Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 218

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Treatment of toxoplasmosis: Current options and future perspectives

Open access
Konstantinovic, Neda, Guegan, Hélène, Stäjner, Tijana, Belaz, Sorya, Robert-Gangneux, Florence · 2019 · Food and Waterborne Parasitology

Abstract

Toxoplasmosis is a worldwide parasitic disease infecting about one third of humans, with possible severe outcomes in neonates and immunocompromised patients. Despite continuous and successful efforts to improve diagnosis, therapeutic schemes have barely evolved since many years. This article aims at reviewing the main clinical trials and current treatment practices, and at addressing future perspectives in the light of ongoing researches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.fawpar.2019.e00036

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 146

  1. Adeyemi, 2018, Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents, Parasitol. Res., 117, 355, 10.1007/s00436-017-5698-1 · doi:10.1007/s00436-017-5698-1
  2. Adriaensen, 2018, Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients, Front. Immunol., 8, 10.3389/fimmu.2017.01943 · DOI
  3. Afifi, 2015, The immunomodulatory effects of rolipram abolish drug-resistant latent phase of Toxoplasma gondii infection in a murine model, J. Microsc. Ultrastruct., 3, 86, 10.1016/j.jmau.2014.12.001 · DOI
  4. Alday, 2017, Drugs in development for toxoplasmosis: advances, challenges, and current status, Drug Des. Devel. Ther., 11, 273, 10.2147/DDDT.S60973 · DOI · Paper page
  5. Arens, 2007, Treating AIDS-associated cerebral toxoplasmosis - pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids, S. Afr. Med. J., 97, 956
  6. Baatz, 2006, Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient, Ocul. Immunol. Inflamm., 14, 185, 10.1080/09273940600659740 · doi:10.1080/09273940600659740
  7. Bahrami, 2015, Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major, Parasitol. Res., 114, 4617, 10.1007/s00436-015-4707-5 · doi:10.1007/s00436-015-4707-5
  8. Ben-Harari, 2017, Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review, Drugs in R&D, 17, 523, 10.1007/s40268-017-0206-8 · DOI · Paper page
  9. Benmerzouga, 2015, Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis, Antimicrob. Agents Chemother., 59, 6939, 10.1128/AAC.01683-15 · DOI
  10. Bhadra, 2010, Absence of both IL-7 and IL-15 severely impairs the development of CD8 T cell response against Toxoplasma gondii, PLoS One, 5, 10.1371/journal.pone.0010842 · DOI
  11. Bhadra, 2011, The CD8 T-cell road to immunotherapy of toxoplasmosis, Immunotherapy, 3, 789, 10.2217/imt.11.68 · DOI
  12. Bhadra, 2011, Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade, Proc. Natl. Acad. Sci. U. S. A., 108, 9196, 10.1073/pnas.1015298108 · DOI · Paper page
  13. Bhadra, 2012, PD-1–mediated attrition of polyfunctional memory CD8+ T cells in chronic Toxoplasma infection, J. Infect. Dis., 206, 125, 10.1093/infdis/jis304 · DOI
  14. Bhadra, 2013, ‘Donor CD8 + T cells prevent Toxoplasma gondii de-encystation but fail to rescue the exhausted endogenous CD8 + T cell population’, Infection and Immunity, Edited by J. L. Flynn, 81, 3414
  15. Bosch-Driessen, 2002, A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, Am J. Ophthalmol., 134, 34, 10.1016/S0002-9394(02)01537-4 · doi:10.1016/s0002-9394(02)01537-4
  16. Bougdour, 2009, Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites, J. Exp. Med., 206, 953, 10.1084/jem.20082826 · DOI · Paper page
  17. Boyom, 2014, Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica, Antimicrob. Agents Chemother., 58, 5848, 10.1128/AAC.02541-14 · DOI
  18. Butler, 2013, Ocular toxoplasmosis II: clinical features, pathology and management, Clin. Exp. Ophthalmol., 41, 95, 10.1111/j.1442-9071.2012.02838.x · doi:10.1111/j.1442-9071.2012.02838.x
  19. Cai, 2000, Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii, Infect. Immun., 68, 6932, 10.1128/IAI.68.12.6932-6938.2000 · DOI · Paper page
  20. Campbell, 2006, First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation, Transplantation, 81, 408, 10.1097/01.tp.0000188183.49025.d5 · doi:10.1097/01.tp.0000188183.49025.d5
  21. Cha, 2001, Effects of specific monoclonal antibodies to dense granular proteins on the invasion of Toxoplasma gondii in vitro and in vivo, Korean J. Parasitol., 39, 233, 10.3347/kjp.2001.39.3.233 · DOI
  22. Chirgwin, 2002, Clin. Infect. Dis., 34, 1243, 10.1086/339551 · doi:10.1086/339551
  23. Chung, 2008, Bilateral Toxoplasma Retinochoroiditis simulating cytomegalovirus retinitis in an allogeneic bone marrow transplant patient, Korean J. Ophthalmol., 22, 197, 10.3341/kjo.2008.22.3.197 · doi:10.3341/kjo.2008.22.3.197
  24. Cortina-Borja, 2010, Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study, PLoS Med., 7, 10.1371/journal.pmed.1000351 · DOI · Paper page
  25. Daffos, 1988, Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis, N. Engl. J. Med., 318, 271, 10.1056/NEJM198802043180502 · DOI
  26. Dannemann, 1992, Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California collaborative treatment group, Ann. Intern. Med., 116, 33, 10.7326/0003-4819-116-1-33 · DOI · Paper page
  27. de Kock, 2018, Population pharmacokinetic properties of sulfadoxine and pyrimethamine: a pooled analysis to inform optimal dosing in African children with uncomplicated malaria, Antimicrob. Agents Chemother., 62, 10.1128/AAC.01370-17 · DOI
  28. Deckert-Schlüter, 1997, Interleukin-10 downregulates the intracerebral immune response in chronic Toxoplasma encephalitis, J. Neuroimmunol., 76, 167, 10.1016/S0165-5728(97)00047-7 · DOI
  29. Desmonts, 1974, Toxoplasmosis in pregnancy and its transmission to the fetus, Bull. N. Y. Acad. Med., 50, 146
  30. Dhakal, 2018, Toxoplasmosis in the non-orthotopic heart transplant recipient population, how common is it? Any indication for prophylaxis?, Curr. Opin. Organ Transplant., 23, 407, 10.1097/MOT.0000000000000550 · doi:10.1097/mot.0000000000000550
  31. Dittmar, A. J., Drozda, A. A. and Blader, I. J. (2016) ‘Drug repurposing screening identifies novel compounds that effectively inhibit Toxoplasma gondii growth’, mSphere, 1(2). doi:https://doi.org/10.1128/mSphere.00042-15. · DOI
  32. Djurković-Djaković, 1999, Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis, Antimicrob. Agents Chemother., 43, 2240, 10.1128/AAC.43.9.2240 · doi:10.1128/aac.43.9.2240
  33. Djurković-Djaković, 2002, Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii, J. Antimicrob. Chemother., 50, 981, 10.1093/jac/dkf251 · doi:10.1093/jac/dkf251
  34. Docampo, 1978, Lipid peroxidation and the generation of free radicals, superoxide anion, and hydrogen peroxide in beta-lapachone-treated Trypanosoma cruzi epimastigotes, Arch. Biochem. Biophys., 186, 292, 10.1016/0003-9861(78)90438-1 · DOI
  35. Doggett, 2012, Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis, Proc. Natl. Acad. Sci. U. S. A., 109, 15936, 10.1073/pnas.1208069109 · DOI · Paper page
  36. Doggett, 2014, Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection, Antimicrob. Agents Chemother., 58, 3547, 10.1128/AAC.01823-13 · DOI
  37. Doliwa, 2013, Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of toxoplasma gondii using difference-gel electrophoresis (DIGE), Int. J. Parasitol., 3, 35
  38. Dunay, 2009, Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model, Antimicrob. Agents Chemother., 53, 4450, 10.1128/AAC.00502-09 · doi:10.1128/aac.00502-09
  39. Dunay, 2018, Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice, Clin. Microbiol. Rev., 31
  40. Eissa, 2015, Could miltefosine be used as a therapy for toxoplasmosis?, Exp. Parasitol., 157, 12, 10.1016/j.exppara.2015.06.005 · DOI
  41. El-Zawawy, 2015, Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii, Acta Trop., 141, 103, 10.1016/j.actatropica.2014.09.020 · DOI
  42. El-Zawawy, 2015, Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis, Exp. Parasitol., 149, 54, 10.1016/j.exppara.2014.12.007 · DOI
  43. Escotte-Binet, 2018, Metallopeptidases of Toxoplasma gondii: in silico identification and gene expression, Parasite, 25, 26, 10.1051/parasite/2018025 · DOI
  44. Etewa, 2018, Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice, J. Parasit. Dis., 42, 102, 10.1007/s12639-017-0973-8 · DOI
  45. Ferguson, 1994, An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii, Int. J. Exp. Pathol., 75, 111
  46. Fernàndez-Sabé, 2012, Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study, Clin. Infect. Dis., 54, 355, 10.1093/cid/cir806 · doi:10.1093/cid/cir806
  47. Ferreira, 2002, Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection, Parasite, 9, 261, 10.1051/parasite/2002093261 · doi:10.1051/parasite/2002093261
  48. Ferreira, 2006, Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1′-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine, Exp. Parasitol., 113, 125, 10.1016/j.exppara.2005.12.006 · doi:10.1016/j.exppara.2005.12.006
  49. Ferreira, 2012, New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains, Exp. Parasitol., 132, 450, 10.1016/j.exppara.2012.09.003 · doi:10.1016/j.exppara.2012.09.003
  50. Foulon, 1999, Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters, Am. J. Obstet. Gynecol., 181, 843, 10.1016/S0002-9378(99)70311-X · doi:10.1016/s0002-9378(99)70311-x
  51. Freeman, 2008, Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study, Pediatrics, 121, e1215, 10.1542/peds.2007-2169 · doi:10.1542/peds.2007-2169
  52. Fu, 2011, Generation of a neutralizing human monoclonal antibody fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites, Infect. Immun., 79, 512, 10.1128/IAI.00969-10 · doi:10.1128/iai.00969-10
  53. Fung, 1996, Treatment regimens for patients with toxoplasmic encephalitis, Clin. Ther., 18, 1037, 10.1016/S0149-2918(96)80059-2 · doi:10.1016/s0149-2918(96)80059-2
  54. Gajurel, 2015, Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendations, Curr. Opin. Infect. Dis., 28, 283, 10.1097/QCO.0000000000000169 · doi:10.1097/qco.0000000000000169
  55. Gallant, 2015, Get rich quick with old generic drugs! The Pyrimethamine pricing scandal, Open Forum Infect. Dis., 2, 10.1093/ofid/ofv177 · DOI
  56. Gallino, 1996, Toxoplasmosis in heart transplant recipients, Eur. J. Clin. Microbiol. Infect. Dis., 15, 389, 10.1007/BF01690095 · doi:10.1007/bf01690095
  57. Gazzinelli, 1993, Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts, Proc. Natl. Acad. Sci. U. S. A., 90, 6115, 10.1073/pnas.90.13.6115 · DOI · Paper page
  58. Gazzinelli, 1996, In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha, J. Immunol., 157, 798, 10.4049/jimmunol.157.2.798 · DOI · Paper page
  59. Gilbert, 2003, Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii, BJOG, 110, 112, 10.1046/j.1471-0528.2003.02325.x · DOI
  60. Goswami, 2015, Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting, Int. J. STD AIDS, 26, 864, 10.1177/0956462414560594 · doi:10.1177/0956462414560594
  61. Gras, 2005, Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres, Acta Paediatr., 94, 1721, 10.1111/j.1651-2227.2005.tb01844.x · doi:10.1111/j.1651-2227.2005.tb01844.x
  62. Hegab, 2003, Immunopathogenesis of toxoplasmosis, Clin. Exp. Med., 3, 84, 10.1007/s10238-003-0011-2 · DOI
  63. Hernandez, 2017, A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?, HIV Med., 18, 115, 10.1111/hiv.12402 · doi:10.1111/hiv.12402
  64. Holland, 2002, An update on current practices in the management of ocular toxoplasmosis, Am J. Ophthalmol., 134, 102, 10.1016/S0002-9394(02)01526-X · doi:10.1016/s0002-9394(02)01526-x
  65. Hotop, 2012, Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy, Clin. Infect. Dis., 54, 1545, 10.1093/cid/cis234 · doi:10.1093/cid/cis234
  66. Innes et al., 2019, A one health approach to vaccines against Toxoplasma gondii, Food Waterborne Parasitol.
  67. Jackowski, 1989, Acetoacetyl-acyl carrier protein synthase. A target for the antibiotic thiolactomycin, J. Biol. Chem., 264, 7624, 10.1016/S0021-9258(18)83280-X · DOI
  68. Jacobson, 2001, Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS, AIDS, 15, 583, 10.1097/00002030-200103300-00007 · doi:10.1097/00002030-200103300-00007
  69. Kadri, 2014, The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection, Exp. Parasitol., 145, 135, 10.1016/j.exppara.2014.08.008 · DOI
  70. Kasagi, 2011, PD-1 and autoimmunity, Crit. Rev. Immunol., 31, 265, 10.1615/CritRevImmunol.v31.i4.10 · DOI
  71. Katlama, 1996, Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS, Clin. Infect. Dis., 22, 268, 10.1093/clinids/22.2.268 · DOI · Paper page
  72. Khan, 1996, IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice, J. Immunol., 157, 2103, 10.4049/jimmunol.157.5.2103 · DOI
  73. Khan, 1994, Interleukin-12 enhances murine survival against acute toxoplasmosis, Infect. Immun., 62, 1639, 10.1128/iai.62.5.1639-1642.1994 · DOI · Paper page
  74. Khan, 1995, IL-10 mediates immunosuppression following primary infection with Toxoplasma gondii in mice, Parasite Immunol., 17, 185, 10.1111/j.1365-3024.1995.tb00888.x · DOI
  75. Khan, 1999, Immune CD8(+) T cells prevent reactivation of Toxoplasma gondii infection in the immunocompromised host, Infect. Immun., 67, 5869, 10.1128/IAI.67.11.5869-5876.1999 · doi:10.1128/iai.67.11.5869-5876.1999
  76. Kieffer, 2008, Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis, Pediatr. Infect. Dis. J., 27, 27, 10.1097/INF.0b013e318134286d · doi:10.1097/inf.0b013e318134286d
  77. Kongsaengdao, 2008, Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients, J. Int. Assoc. Phys. AIDS Care, 7, 11
  78. Lai, 2012, Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections, Proc. Natl. Acad. Sci. U. S. A., 109, 14182, 10.1073/pnas.1208775109 · DOI
  79. Lebech, 1999, Feasibility of neonatal screening for Toxoplasma infection in the absence of prenatal treatment, Danish congenital toxoplasmosis study group’, Lancet, 353, 1834
  80. Lim, 2014, Recent advances in Toxoplasma gondii Immunotherapeutics, Korean J. Parasitol., 52, 581, 10.3347/kjp.2014.52.6.581 · DOI
  81. Lourido, 2010, Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma, Nature, 465, 359, 10.1038/nature09022 · DOI · Paper page
  82. Luft, 1993, Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome, N. Engl. J. Med., 329, 995, 10.1056/NEJM199309303291403 · DOI · Paper page
  83. Lykins, 2018, CSGID solves structures and identifies phenotypes for five enzymes in Toxoplasma gondii, Front. Cell. Infect. Microbiol., 8, 352, 10.3389/fcimb.2018.00352 · DOI
  84. Maldonado, 2017, Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States, Pediatrics, 139, 10.1542/peds.2016-3860 · DOI · Paper page
  85. Mandelbrot, 2018, Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial, Am. J. Obstet. Gynecol., 219, 386.e1, 10.1016/j.ajog.2018.05.031 · doi:10.1016/j.ajog.2018.05.031
  86. Martino, 2005, Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation, Clin. Infect. Dis., 40, 67, 10.1086/426447 · doi:10.1086/426447
  87. Martins-Duarte, 2009, Thiolactomycin analogues as potential anti-Toxoplasma gondii agents, Parasitol. Int., 58, 411, 10.1016/j.parint.2009.08.004 · DOI
  88. Maubon, 2010, Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds, Antimicrob. Agents Chemother., 54, 4843, 10.1128/AAC.00462-10 · DOI
  89. Mazumdar, 2006, Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii, Proc. Natl. Acad. Sci. U. S. A., 103, 13192, 10.1073/pnas.0603391103 · DOI · Paper page
  90. McFadden, 2000, Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance, Mol. Biochem. Parasitol., 108, 1, 10.1016/S0166-6851(00)00184-5 · DOI · Paper page
  91. McFarland, 2016, Review of experimental compounds demonstrating anti-Toxoplasma activity, Antimicrob. Agents Chemother., 60, 7017, 10.1128/AAC.01176-16 · DOI
  92. McLeod, 2006, Outcome of treatment for congenital toxoplasmosis, 1981–2004: the national collaborative Chicago-based, congenital toxoplasmosis study, Clin. Infect. Dis., 42, 1383, 10.1086/501360 · DOI · Paper page
  93. McPhillie, 2016, New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections, Sci. Rep., 6, 10.1038/srep29179 · doi:10.1038/srep29179
  94. Mele, 2002, Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature, Bone Marrow Transplant., 29, 691, 10.1038/sj.bmt.1703425 · doi:10.1038/sj.bmt.1703425
  95. Meneceur, 2008, In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone, Antimicrob. Agents Chemother., 52, 1269, 10.1128/AAC.01203-07 · DOI
  96. Mets, 1996, Eye manifestations of congenital toxoplasmosis, Am J. Ophthalmol., 122, 309, 10.1016/S0002-9394(14)72057-4 · DOI · Paper page
  97. Montazeri, 2017, A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006-2016), Front. Microbiol., 8, 25, 10.3389/fmicb.2017.00025 · DOI · Paper page
  98. Montoya, 2004, Toxoplasmosis, Lancet, 363, 1965, 10.1016/S0140-6736(04)16412-X · DOI · Paper page
  99. Mui, 2008, Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo, PLoS Negl. Trop. Dis., 2, e190, 10.1371/journal.pntd.0000190 · doi:10.1371/journal.pntd.0000190
  100. Müller, 2017, Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis, J. Antimicrob. Chemother., 72, 2334, 10.1093/jac/dkx134 · DOI
  101. Murata, 2017, Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites, PLoS One, 12, 10.1371/journal.pone.0178203 · DOI
  102. Ni Nyoman, 2013, Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept study, Apoptosis, 18, 664, 10.1007/s10495-013-0832-8 · DOI
  103. O'Donnell, 2004, Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4), Trends Pharmacol. Sci., 25, 158, 10.1016/j.tips.2004.01.003 · DOI · Paper page
  104. Ojo, 2014, A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation, J. Infect. Dis., 209, 275, 10.1093/infdis/jit522 · DOI
  105. Opsenica, 2015, Tetraoxanes as inhibitors of apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii and anti-cancer molecules, J. Serb. Chem. Soc., 80, 1339, 10.2298/JSC150430063O · doi:10.2298/jsc150430063o
  106. Ozgonul, 2017, Recent developments in the diagnosis and treatment of ocular toxoplasmosis, Ophthalmic Res., 57, 1, 10.1159/000449169 · DOI
  107. Patel, 1996, Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis, Radiology, 199, 433, 10.1148/radiology.199.2.8668790 · doi:10.1148/radiology.199.2.8668790
  108. Petersen, 2007, Prevention and treatment of congenital toxoplasmosis, Expert Rev. Anti-Infect. Ther., 5, 285, 10.1586/14787210.5.2.285 · doi:10.1586/14787210.5.2.285
  109. Peyron, 2017, Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches, PLoS Negl. Trop. Dis., 11, 10.1371/journal.pntd.0005222 · doi:10.1371/journal.pntd.0005222
  110. Pfaff, 2014, New clinical and experimental insights into Old World and neotropical ocular toxoplasmosis, Int. J. Parasitol., 44, 99, 10.1016/j.ijpara.2013.09.007 · DOI
  111. Phan, 2008, Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life, Am J. Ophthalmol., 146, 375, 10.1016/j.ajo.2008.04.033 · doi:10.1016/j.ajo.2008.04.033
  112. Prusa, A.-R. et al. (2015) ‘Amniocentesis for the detection of congenital toxoplasmosis: results from the nationwide Austrian prenatal screening program’, Clin. Microbiol. Infect., 21(2), pp. 191.e1–8. doi:https://doi.org/10.1016/j.cmi.2014.09.018. · doi:10.1016/j.cmi.2014.09.018
  113. Radke, 2018, Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in Vitro, ACS Infect. Dis., 4, 1264, 10.1021/acsinfecdis.8b00113 · DOI
  114. Rajapakse, 2013, Antibiotics for human toxoplasmosis: a systematic review of randomized trials, Pathog. Glob. Health, 107, 162, 10.1179/2047773213Y.0000000094 · DOI
  115. Ramakrishnan, 2015, The intracellular parasite Toxoplasma gondii depends on the synthesis of long-chain and very long-chain unsaturated fatty acids not supplied by the host cell, Mol. Microbiol., 97, 64, 10.1111/mmi.13010 · DOI
  116. Rezaei, 2018, A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immunization, Microb. Pathog., 126, 172, 10.1016/j.micpath.2018.11.003 · DOI
  117. Robert-Gangneux, 2014, It is not only the cat that did it: how to prevent and treat congenital toxoplasmosis, J. Infect., 68, S125, 10.1016/j.jinf.2013.09.023 · DOI
  118. Robert-Gangneux, 2011, The placenta: a main role in congenital toxoplasmosis?, Trends Parasitol., 27, 530, 10.1016/j.pt.2011.09.005 · doi:10.1016/j.pt.2011.09.005
  119. Robert-Gangneux, 2015, Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study, J. Clin. Microbiol., 53, 1677, 10.1128/JCM.03282-14 · doi:10.1128/jcm.03282-14
  120. Robert-Gangneux, 2018, Toxoplasmosis in transplant recipients, Europe, 2010–2014, Emerg. Infect. Dis., 24, 1497, 10.3201/eid2408.180045 · DOI
  121. Romand, 1993, In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii, Antimicrob. Agents Chemother., 37, 2371, 10.1128/AAC.37.11.2371 · doi:10.1128/aac.37.11.2371
  122. Rothova, 1993, Therapy for ocular toxoplasmosis, Am J. Ophthalmol., 115, 517, 10.1016/S0002-9394(14)74456-3 · DOI · Paper page
  123. Rutaganira, 2017, Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii, J. Med. Chem., 60, 9976, 10.1021/acs.jmedchem.7b01192 · DOI
  124. Saba, 1993, Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS, Eur. J. Clin. Microbiol. Infect. Dis., 12, 853, 10.1007/BF02000407 · doi:10.1007/bf02000407
  125. Schmidt, 2006, The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999–2002, Arch. Dis. Child., 91, 661, 10.1136/adc.2004.066514 · DOI
  126. Schuster, 2006, In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri, J. Eukaryot. Microbiol., 53, 121, 10.1111/j.1550-7408.2005.00082.x · DOI
  127. Shubar, 2008, A new combined flow-cytometry-based assay reveals excellent activity against Toxoplasma gondii and low toxicity of new bisphosphonates in vitro and in vivo, J. Antimicrob. Chemother., 61, 1110, 10.1093/jac/dkn047 · doi:10.1093/jac/dkn047
  128. Signorell, 1996, Cord blood screening for congenital toxoplasmosis in northwestern Switzerland, 1982–1999, Pediatr. Infect. Dis. J., 25, 123, 10.1097/01.inf.0000195542.43369.96 · DOI
  129. Silva, 2017, Genetic polymorphisms and phenotypic profiles of sulfadiazine-resistant and sensitive Toxoplasma gondii isolates obtained from newborns with congenital toxoplasmosis in Minas Gerais, Brazil, PLoS One, 12, 10.1371/journal.pone.0170689 · DOI
  130. Spalenka, 2018, Discovery of new inhibitors of Toxoplasma gondii via the pathogen box, Antimicrob. Agents Chemother., 62, 10.1128/AAC.01640-17 · DOI
  131. Tan, 2010, Monoclonal antibodies against nucleoside triphosphate hydrolase-II can reduce the replication of Toxoplasma gondii, Parasitol. Int., 59, 141, 10.1016/j.parint.2009.12.007 · DOI
  132. Teimouri, 2018, Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain, Int. J. Nanomedicine, 13, 1341, 10.2147/IJN.S158736 · DOI
  133. Thiébaut, 2007, Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data, Lancet, 369, 115, 10.1016/S0140-6736(07)60072-5 · DOI · Paper page
  134. Torre, 1998, Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian collaborative study group, Antimicrob. Agents Chemother., 42, 1346, 10.1128/AAC.42.6.1346 · doi:10.1128/aac.42.6.1346
  135. Torres, 1997, Atovaquone for salvage treatment and suppression of Toxoplasmic encephalitis in patients with AIDS, Clin. Infect. Dis., 24, 422, 10.1093/clinids/24.3.422 · doi:10.1093/clinids/24.3.422
  136. Valentini, 2009, Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy, Eur. J. Clin. Microbiol. Infect. Dis., 28, 297, 10.1007/s10096-008-0612-5 · doi:10.1007/s10096-008-0612-5
  137. Vidadala, 2016, Development of an orally available and central nervous system (CNS) penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitor with minimal human ether-a-go-go-related gene (hERG) activity for the treatment of toxoplasmosis, J. Med. Chem., 59, 6531, 10.1021/acs.jmedchem.6b00760 · DOI
  138. Villena, 1998, Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims toxoplasmosis group, Scand. J. Infect. Dis., 30, 295, 10.1080/00365549850160963 · DOI
  139. Wallon, M. et al. (2013) ‘Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years’, Clin. Infect. Dis., 56(9), pp. 1223–1231. doi:https://doi.org/10.1093/cid/cit032. · DOI · Paper page
  140. Wang, 2017, Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis, Lancet HIV, 4, e177, 10.1016/S2352-3018(17)30005-X · DOI · Paper page
  141. Webster, 2012, Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier, Am. J. Trop. Med. Hyg., 87, 715, 10.4269/ajtmh.2012.12-0100 · doi:10.4269/ajtmh.2012.12-0100
  142. Wei, 2015, A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans, PLoS One, 10, 10.1371/journal.pone.0138204 · doi:10.1371/journal.pone.0138204
  143. Wilson, 1980, Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection, Pediatrics, 66, 767, 10.1542/peds.66.5.767 · DOI · Paper page
  144. Yap, 2000, Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii, J. Immunol., 165, 628, 10.4049/jimmunol.165.2.628 · DOI · Paper page
  145. Yarovinsky, 2014, Innate immunity to Toxoplasma gondii infection, Nat. Rev. Immunol., 14, 109, 10.1038/nri3598 · DOI · Paper page
  146. You, 2017, Silver nanoparticle loaded collagen/chitosan scaffolds promote wound healing via regulating fibroblast migration and macrophage activation, Sci. Rep., 7, 10.1038/s41598-017-10481-0 · DOI · Paper page

Cited by

See all 218

Metadata

Authors
Konstantinovic, N., Guegan, H., Stäjner, T., Belaz, S., & Robert-Gangneux, F.
Venue
Food and Waterborne Parasitology
Publisher
Elsevier BV
Published
2019-06
Volume
15
Pages
e00036
ISSN
2405-6766 (ISSN-L)
OpenAlex
W2926432634
Cited by
218
References
1
FWCI
13.39
Type
journal article
Language
en
Update notices
erratum (2020-12-01)
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.